

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ab&B Bio-Tech CO., LTD. JS**

**江蘇中慧元通生物科技股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 2627)**

## **VOLUNTARY ANNOUNCEMENT**

### **COMMENCEMENT OF PHASE I CLINICAL TRIAL FOR ADJUVANTED QUADRIVALENT SUBUNIT INFLUENZA VACCINE AND ADJUVANTED TRIVALENT SUBUNIT INFLUENZA VACCINE**

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**” or “**Ab&B Bio-Tech**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Group has recently initiated Phase I clinical trials of the Group’s adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine. We obtained Investigational New Drug approvals from the National Medical Products Administration of the People’s Republic of China for our adjuvanted quadrivalent subunit influenza vaccine candidate in July 2024 and our adjuvanted trivalent subunit influenza vaccine candidate in October 2024.

The impact of influenza on the elderly, particularly those over the age of 65, is more severe due to the natural decline in immune function with age. This demographic is at heightened risk for severe illness and mortality from influenza infections, leading to significant health impacts and economic burdens. Our adjuvanted quadrivalent subunit influenza vaccine and adjuvanted trivalent subunit influenza vaccine targets individuals aged 65 and above, offering an enhanced immune response due to its MF59-like adjuvant, which boosts antibody titers for better protection in this age group.

#### **About Ab&B Bio-Tech**

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

This announcement is published on a voluntary basis by the Company. **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Ab&B Bio-Tech CO., LTD. JS**  
**Mr. AN Youcai**

*Executive Director, chairman of our Board and general manager*

Hong Kong, November 13, 2025

*As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non-executive Directors.*